BioLife Solutions Inc. (BLFS)

Price$26.65

Value ScoreF

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-7.36%

Price vs S&P 500 (4W)20.93%

VGM Score48.77

Market Capitalization$1.30B

All Metrics

P/CF (Annual)64.73x

Book Value / Share (Quarterly)$7.62

P/TBV (Annual)3.17x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.91%

Cash Flow / Share (Quarterly)$-0.05

Price vs S&P 500 (YTD)2.06%

Gross Margin (TTM)63.97%

Net Profit Margin (TTM)-2.97%

EPS (TTM)$-0.06

10-Day Avg Trading Volume0.86M

EPS Excl Extra (TTM)$-0.06

Revenue Growth (5Y)14.87%

EPS (Annual)$-0.10

ROI (Annual)-1.22%

Gross Margin (Annual)64.56%

Net Profit Margin (5Y Avg)-34.13%

Cash / Share (Quarterly)$1.66

Revenue Growth QoQ (YoY)14.87%

ROA (Last FY)-1.13%

Revenue Growth TTM (YoY)25.63%

EBITD / Share (TTM)$-0.28

ROE (5Y Avg)-13.48%

Operating Margin (TTM)-15.39%

Cash Flow / Share (Annual)$-0.01

P/B Ratio3.50x

P/B Ratio (Quarterly)2.48x

Net Income / Employee (Annual)$-29,600

EV / Revenue (TTM)12.85x

Net Interest Coverage (TTM)-0.82x

ROA (TTM)-0.75%

EPS Growth QoQ (YoY)-13.93%

EV / EBITDA (TTM)971.01x

EPS Incl Extra (Annual)$-0.10

Current Ratio (Annual)5.94x

Quick Ratio (Quarterly)5.15x

3-Month Avg Trading Volume0.50M

52-Week Price Return23.95%

EV / Free Cash Flow (Annual)403.10x

Revenue / Employee (TTM)$643,700

Tangible BV / Share (Quarterly)$7.54

P/S Ratio (Annual)13.53x

Asset Turnover (Annual)0.24x

52-Week High$29.62

Operating Margin (5Y Avg)-29.03%

EPS Excl Extra (Annual)$-0.10

CapEx CAGR (5Y)21.39%

Tangible BV CAGR (5Y)16.11%

26-Week Price Return0.57%

Quick Ratio (Annual)4.22x

13-Week Price Return32.46%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)7.30x

Enterprise Value$1.28B

Revenue / Share Growth (5Y)2.72%

Asset Turnover (TTM)0.25x

Book Value / Share Growth (5Y)4.41%

Revenue / Employee (Annual)$620,700

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)-12.56%

Cash / Share (Annual)$1.84

3-Month Return Std Dev47.44%

Gross Margin (5Y Avg)43.72%

Net Income / Employee (TTM)$-19,100

ROE (Last FY)-1.24%

Net Interest Coverage (Annual)-3.91x

EPS Basic Excl Extra (Annual)$-0.10

P/FCF (TTM)303.65x

Receivables Turnover (TTM)8.98x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-0.06

Receivables Turnover (Annual)11.24x

ROI (TTM)-0.81%

P/S Ratio (TTM)13.05x

Pretax Margin (5Y Avg)-29.13%

Revenue / Share (Annual)$2.01

Tangible BV / Share (Annual)$7.63

Forward P/E99.10x

Price vs S&P 500 (52W)-0.41%

Year-to-Date Return10.22%

5-Day Price Return0.08%

EPS Normalized (Annual)$-0.10

ROA (5Y Avg)-11.06%

Net Profit Margin (Annual)-4.78%

Month-to-Date Return6.94%

Cash Flow / Share (TTM)$-2.09

EBITD / Share (Annual)$-0.34

Operating Margin (Annual)-17.26%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)72.75x

ROI (5Y Avg)-12.62%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.06

P/TBV (Quarterly)2.50x

P/B Ratio (Annual)3.13x

Inventory Turnover (TTM)1.19x

Pretax Margin (TTM)-10.42%

Book Value / Share (Annual)$7.72

Price vs S&P 500 (13W)24.20%

Beta1.95x

P/FCF (Annual)459.12x

Revenue / Share (TTM)$2.03

ROE (TTM)-0.82%

52-Week Low$17.86

vGradeF

gGradeB

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.02est. 0.02

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.19

Industry Peers — Electromedical Equipment(31)

Symbol	Value Score	Growth Score	Momentum Score	Price
BLFSBioLife Solutions Inc.	F	B	B	$26.65
MDTMedtronic plc	B	C	C	$81.67
MASIMasimo Corporation	D	D	B	$178.82
LIVNLivaNova PLC Ordinary Shares	C	C	B	$72.36
ITGRInteger Holdings Corporation	B	C	C	$91.98
TMDXTransMedics Group, Inc. Common Stock	C	B	D	$69.43
AXGNAxogen, Inc. Common Stock	F	B	A	$42.80
CNMDCONMED Corporation	A	C	D	$35.16
INMDInMode Ltd. Ordinary Shares	A	D	C	$13.54
CBLLCeriBell, Inc. Common Stock	D	A	B	$18.25
CVCapsoVision, Inc. Common Stock	F	D	A	$7.19

About

BioLife Solutions provides bioproduction solutions for the cell and gene therapy industry, including cell processing, cold chain, and thawing technologies designed to optimize manufacturing efficiency. The company's primary revenue driver is CryoStor, a biopreservation product for cell processing applications. The vast majority of revenue is generated in the United States market.